Subcutaneous versus IV piperacillin/tazobactam for adults with serious bacterial infections

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 randomized trial compares continuous subcutaneous infusion of piperacillin/tazobactam with the standard continuous intravenous infusion in adults who require 18 g/day of the drug combination for severe bacterial infections. Participants are randomized to one of the two delivery routes and will have timed blood sampling for pharmacokinetic analysis. Safety, clinical response, and end-of-treatment outcomes will be recorded to determine whether the subcutaneous route is not clinically worse than the IV route. The study focuses on drug exposure, feasibility of subcutaneous administration, and adverse events during the treatment period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Free, written and informed consent signed by the participant;
* At least 18 years old on the day of inclusion;
* Male and female participants;
* Clinical indication for treatment with piperacillin/tazobactam 18g/die in continuous infusion, including severe pneumonia, neutropenic fever suspected to be caused by bacterial infection or other severe bacterial infections for which, based on investigator's judgment, this dosage regimen is appropriate;
* Evidence of postmenopausal status, defined as no menses for at least 12 consecutive months without an alternative medical cause and, if clinically indicated, confirmed by serum FSH levels in the postmenopausal range; or Negative serum pregnancy test at the screening visit (sensitivity ≥25 mIU/mL) and negative urine β-HCG test at the End-of-Treatment (D8) for females of childbearing potential who are sexually active with a non-sterilized male partner.

Women of childbearing potential (WOCBP) are defined as all women who are not surgically sterile (bilateral salpingectomy, bilateral oophorectomy, or complete hysterectomy) and who are not postmenopausal;

\- Admitted to one of the wards authorized for the enrollment.

Exclusion Criteria:

* Known hypersensitivity to penicillins, cephalosporins, other β-lactamase inhibitors, or any component of the formulation;
* Pregnant or breastfeeding women, and women intending to become pregnant during the study or within the End-of-Treatment visit;
* Women of childbearing potential (WOCBP) unwilling or unable to use at least one highly effective method of contraception, as defined in Section 7.4, throughout study participation and for at least at the End-of-Treatment visit;
* No indication for treatment with TZP;
* Known resistance to TZP;
* Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications;
* Participation in another clinical trial with administration of an investigational medicinal product (IMP) within 30 days prior to screening or within 5 half-lives of that IMP, whichever is longer.

Where it's running

• Azienda Sanitaria Universitaria Friuli Centrale
  Udine, Italia/UD, Italy Recruiting

Study contacts

• Principal investigator: Carlo Tascini, Professor — Azienda Sanitaria Universitaria Friuli Centrale
• Study coordinator: Carlo Tascini, Full Professor
• Email: carlo.tascini@uniud.it
• Phone: +39-0432-559355

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Predicting Death in ICU Patients with Multidrug-Resistant Gram-Negative Infections

  This study tests whether a Mortality risk model can predict outcomes for critically ill adults in the ICU who are colonized or infected with multidrug-resistant Gram-negative bacteria.

  Recruiting Fundacion SEIMC-GESIDA · Madrid, Madrid · NCT07749508

• Investigating Staphylococcus aureus in the nose of patients with bacteremia

  This study is trying to see if Staphylococcus aureus bacteria found in the nose of patients with blood infections can affect their treatment and recovery.

  Recruiting Centre Hospitalier Universitaire de Saint Etienne · Saint-Etienne · NCT06594250

• Intravenous polymyxin B and colistin for carbapenem-resistant gram-negative infections

  This study looks to see how well intravenous polymyxin B and colistin work and how safe they are in adults with carbapenem-resistant gram-negative bloodstream or lung infections.

  Recruiting TTY Biopharm · Taipei · NCT06966284

• Evaluating Fluorothiazinone for Preventing Bacterial Infections in Ventilated Patients

  This study is testing if a new drug called Fluorothiazinone can help prevent bacterial infections in patients on ventilators in the ICU.

  Recruiting at 2 sites Phase 2 Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation · Moscow, Moscow and 1 other locations · NCT06135350

• Using fecal microbiota transplantation to prevent infections after liver transplantation

  This study is testing if a special treatment using healthy stool can help prevent infections in people getting a liver transplant.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna · NCT06782880

• Fermented dairy product and bifidobacteria diversity in adults

  This study tests whether consuming a fermented dairy product changes gut bacteria diversity in healthy adults aged 45–60 compared with a control product.

  Recruiting Danone Global Research & Innovation Center · Dijon · NCT07700381

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.